Prevalence of Soft Tissue Sarcoma (STS) Subtypes in the US, Risk of Metastases at Diagnosis, and Survival Outcomes
Soft tissue sarcomas (STS) are heterogeneous malignancies with diverse clinical presentations and outcomes.
This study examines the prevalence, metastatic risk, and survival impact of various STS subtypes. By characterizing the disease landscape, we aim to inform treatment strategies, resource allocation, and clinical trial design, ultimately improving patient outcomes.
Click here to download our White paper.
Jump to a slide with the slide dots.
Decentralized Clinical Trials Global Trends: Positive Impacts and Advances
As summer of 2025 begins, it is reasonable to contemplate the extreme impact of substantial growth with general remote activities within in recent yea
Read more
Anthony Haywood
Risk Management in Clinical Trials: Navigating Uncertainty with Precision
In the high-stakes world of clinical trials, risk management isn’t just a regulatory checkbox, it’s the backbone of scientific integrity and operation
Read more
Clinical trial site and sponsor engagement: Ongoing trend impacts & communication strategies.
Clinical trial sponsor and site engagement communication pathways lay the foundation for study performance and data outcomes. In this insight, Blair S
Read more
EMA now needs patient experience data from R&D to access
While patients are valuable contributors across the medicines development lifecycle, patient experience data (PED) are still not systematically includ
Read more
Clinical trial recruitment is not operational, it’s strategic. Let’s stop pretending otherwise.
There is a quiet fiction at the heart of many clinical trials. It goes something like this: “once the protocol is...
Read more